Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00908 ...
Drug Name Quinidine
Molecular Weight 324.4168
Molecular Formula C20H24N2O2
CAS Number 56-54-2
SMILES [H][C@@]12CCN(C[C@@H]1C=C)[C@]([H])(C2)[C@@H](O)C1=C2C=C(OC)C=CC2=NC=C1
External Links
DRUGBANK DB00908
PubChem Compound 441074
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability -4.69 - -4.69 - ADME Research, USCD
Log P 3.44 - 3.44 - HANSCH,C ET AL. (1995)
Melting Point 174.0 ℃ 174 ℃ PhysProp
Water Solubility 140.0 mg/L 140 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
pKa 8.56 - 8.56 - SANGSTER (1994)
Log S -3.37 - -3.37 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 80.0 % 80±15 % PO, oral; Derivative; The Pharmacological Basis of Therapeutics
Bioavailability 71.0 % 71±17 % PO, oral; Derivative; The Pharmacological Basis of Therapeutics
C Max 1300.0 ng/ml ~1.3 mcg/ml PO, oral; immediate release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 530.0 ng/ml 0.53±0.22 mcg/ml PO, oral; extended release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 2900.0 ng/ml 2.9±1.0 mcg/ml intravenous injection, IV; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 2.0 h 1-3 h PO, oral; immediate release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 6.3 h 6.3±3.2 h PO, oral; extended release formulation; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.24 L/h/kg 3.0-5 ml/min/kg adults; DRUGBANK
Clearance 0.28 L/h/kg 4.7±1.8 ml/min/kg hydrolysis; Elderly ↓ ;Hepatic cirrhosis, cirr → ;congestive heart disease ↓ ;Somking → ; The Pharmacological Basis of Therapeutics
Clearance 0.24 L/h/kg 4 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 2.5 L/kg 2.0-3 L/kg DRUGBANK
Volume of Distribution 0.50 L/kg 0.5 L/kg heart disease; DRUGBANK
Volume of Distribution 4.0 L/kg 3.0-5 L/kg Hepatitis, Hep; DRUGBANK
Volume of Distribution 2.7 L/kg 2.7±1.2 L/kg Elderly → ;Hepatic cirrhosis, cirr ↑ ;congestive heart disease ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 2.9 L/kg 2.9 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 7.0 h 6-8 h DRUGBANK
Half-life 6.2 h 6.2±1.8 h Hepatic cirrhosis, cirr ↑ ;congestive heart disease → ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 12.0 h 12±3 h Active metabolite; The Pharmacological Basis of Therapeutics
Half-life 6.6 h 6.6 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 20.0 % ~20 % Urinary excretion; Uric acid; Unchanged drug; DRUGBANK
Eliminate Route 5.0 % 5 % Urinary excretion; Urine alkaline; Unchanged drug; DRUGBANK
Eliminate Route 18.0 % 18±5 % Urinary excretion; Unchanged drug; congestive heart disease → ; The Pharmacological Basis of Therapeutics
Protein Binding 84.0 % 80-88 % DRUGBANK
Protein Binding 87.0 % 87±3 % Neonates ↓ ;Preg, pregnant ↓ ;Elderly → ;Hepatitis, Hep ↓ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia → ;chronic respiratory insufficiency → ;HL,hyperlipoproteinemia → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Not Available

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1